Bryce is the newest PhD candidate and member of the Cancer Signalling Research Group under the supervision of Prof Matt Dun. Bryce’s project will build upon RUN DIPG scholar Mika Persson’s research exploring the immune landscape of DIPG/DMG tumours and will
develop cancer specific therapies like chimeric antigen receptor (CAR) T cells. CAR T cells are a type of “living drug” which are a new and exciting form of cancer treatment called immunotherapies. CAR T cell technology utilises white blood cells taken from
patients that are genetically modified and grown in the lab to target a cancer protein which we then then given back to patients to selectively kill their own cancer. Bryce will build on his three years of experience working with CAR T cells across several
cancers including DIPG/DMG, as well as his Honours project where he received the Neil and Norma Hill Foundation award for best translation research project, investigating new safety mechanism to improve CAR T cell therapy.
We are so proud to be supporting his research through our recent funding of A/Prof Matt Dun and look forward to his updates.
In just a few months in the role he has won a presentation award at the Australian Paediatric Immunotherapy Conference on his work developing a new immunotherapy (chimeric antigen recptor T cell therapy or ‘CART’) for DIPG, the data is very exciting!!